Market for paclitaxel injection in China worth $67 million

Currently, paclitaxel injections are widely used to cure cancers such as non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world, notes a new report from MarketsandMarkets. Paclitaxel injection production values had reached $67.21 million for China in 2009, accounting for 10% of the world total. Moreover, the report notes, China has become one of the most important consumption markets in the world.

The Chinese paclitaxel injection industry has witnessed significant development from 2005-2009. On the one hand, since 2005, China's government has issued a series of policies related to the pharmaceutical industry like health care reform. On the other hand, paclitaxel injection has become the second largest market share in natural anticancer drugs in China, thanks to its good clinical impact and fewer side effects than some other drugs.

For Chinese paclitaxel injection manufacturers, the active pharmaceutical ingredient (paclitaxel APIs) play an important role for them to expend. Due to the increasing cultivation and planting of yew, the price of APIs has gradually declined, thus pushing down the cost of paclitaxel injections. Besides, by the end of June 2010, the Chinese government had adjusted the export tax rebate rate of paclitaxel injections.